| Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy (NCT04745559) | H. Lee Moffitt Cancer Center and Research Institute | 2021-02-18 |
| CAR-T Cell Immunotherapy in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma (NCT02819583) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2016-10-01 |
| Study Evaluating the Efficacy and Safety of PCAR-019 in CD19 Positive Relapsed or Refractory Leukemia and Lymphoma (NCT02851589) | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | 2016-07-01 |
| Pilot Study of Redirected Autologous T Cells Engineered to Contain Humanized Anti-CD19 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma Previously Treated With Cell Therapy (NCT02374333) | University of Pennsylvania | 2014-03-25 |
| Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma (NCT01943682) | Children's Hospital Medical Center, Cincinnati | 2013-09-01 |
| Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma (NCT01685606) | Brown University | 2013-03-01 |
| Treatment for Advanced B-Cell Lymphoma (NCT01859819) | New York Medical College | 2013-01-01 |
| AMG 319 Lymphoid Malignancy FIH (NCT01300026) | Amgen | 2011-04-01 |
| Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients (NCT00949741) | Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie | 2009-07-01 |
| Study of Repeat Intranodal Injections of Ad-ISF35 (NCT00942409) | Januario Castro, M.D. | 2009-06-01 |
| Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat (NCT00791011) | Amgen | 2008-02-01 |
| Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation (NCT00591630) | M.D. Anderson Cancer Center | 2007-11-14 |
| A Trial in Patients With Diffuse Large-B-cell Lymphoma Comparing Pixantrone Against Doxorubicin (NCT00268853) | CTI BioPharma | 2005-11-01 |
| Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies (NCT00275431) | Ascenta Therapeutics | 2005-11-01 |
| Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (NCT00598624) | IRCCS San Raffaele | 2005-09-01 |
| Early On-therapy PET at First-line Treatment in Diffuse Large B-cell Lymphoma Stage IIB-IV (NCT00286832) | Copenhagen University Hospital at Herlev | 2005-08-01 |
| ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1 (NCT00140595) | Lymphoma Study Association | 2003-12-01 |
| R-CHOP-14 Versus R-CHOP-21 and Darbepoetin Alpha in Patients Aged 60-80 Years With Diffuse Large B-cell Lymphoma (NCT00144755) | Lymphoma Study Association | 2003-12-01 |
| ACVBP Versus ACVBP Plus Rituximab in Low Risk Localized Diffuse Large B-cell Lymphoma (NCT00140660) | Lymphoma Study Association | 2003-12-01 |
| ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma (NCT00144807) | Lymphoma Study Association | 2003-12-01 |
| Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma (NCT00169195) | Lymphoma Study Association | 2003-04-01 |
| Rituximab After Autologous Stem Cell Transplant for Relapsed B-cell Non-Hodgkin's Lymphoma (NCT00225212) | Stanford University | 1997-11-01 |